Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history.

Novo Nordisk slightly improved its full-year guidance, but still expects both sales and profit to decline for the year. The update comes after the fastest-ever uptake of its Wegovy weight-loss drug, signaling that growth remains strong in the product but not enough to prevent weaker annual earnings. The guidance revision is a modest positive against a still-negative earnings backdrop.

Analysis

Novo Nordisk slightly improved its full-year guidance, but still expects both sales and profit to decline for the year. The update comes after the fastest-ever uptake of its Wegovy weight-loss drug, signaling that growth remains strong in the product but not enough to prevent weaker annual earnings. The guidance revision is a modest positive against a still-negative earnings backdrop.